Expert Interview
Discussing Crenessity (crinecerfont) in CAH and the potential of atumelnant, an oral ACTH antagonist in development by Crinetics
Ticker(s): NBIX, CRNXInstitution: UCLA Health
- Clinical Endocrinologist and Program Director for the Endocrinology Fellowship Program at UCLA
- Manages 10 CAH patients
- Familiar with commercial and investigational agents in CAH
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
